$NBIX NEUROCRINE BIOSCIENCES INC Insider Trading Week 15/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEUROCRINE BIOSCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NEUROCRINE BIOSCIENCES INC in week 15/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | MOLLICA JOSEPH A | Director | Option Exercise | M | 3.40 | 20,000 | 68,000 | 0 | |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | MOLLICA JOSEPH A | Director | Payment of Exercise | F | 51.80 | 1,312 | 67,962 | 56,042 | 57.4 K to 56 K (-2.29 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | MOLLICA JOSEPH A | Director | Buy | M | 3.40 | 20,000 | 68,000 | 57,354 | 37.4 K to 57.4 K (+53.54 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | OBrien Christopher Flint | Chief Medical Offic ... | Sell | S | 51.23 | 204 | 10,451 | 48,973 | 49.2 K to 49 K (-0.41 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | OBrien Christopher Flint | Chief Medical Offic ... | Sell | S | 50.41 | 12,861 | 648,323 | 49,177 | 62 K to 49.2 K (-20.73 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 51.23 | 204 | 10,451 | 13,017 | 13.2 K to 13 K (-1.54 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 50.41 | 12,861 | 648,323 | 13,221 | 26.1 K to 13.2 K (-49.31 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lippoldt Darin | Chief Legal Officer | Sell | S | 51.23 | 204 | 10,451 | 13,157 | 13.4 K to 13.2 K (-1.53 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lippoldt Darin | Chief Legal Officer | Sell | S | 50.41 | 12,861 | 648,323 | 13,361 | 26.2 K to 13.4 K (-49.05 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Grigoriadis Dimitri E. | Chief Research Offi ... | Sell | S | 51.23 | 204 | 10,451 | 127,691 | 127.9 K to 127.7 K (-0.16 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Grigoriadis Dimitri E. | Chief Research Offi ... | Sell | S | 50.41 | 12,861 | 648,323 | 127,895 | 140.8 K to 127.9 K (-9.14 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 51.23 | 306 | 15,676 | 332,607 | 332.9 K to 332.6 K (-0.09 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 50.41 | 19,290 | 972,409 | 332,913 | 352.2 K to 332.9 K (-5.48 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 51.23 | 204 | 10,451 | 73,246 | 73.5 K to 73.2 K (-0.28 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 50.41 | 12,861 | 648,323 | 73,450 | 86.3 K to 73.5 K (-14.90 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Bozigian Haig P. | Chief Development O ... | Sell | S | 51.23 | 204 | 10,451 | 129,601 | 129.8 K to 129.6 K (-0.16 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Bozigian Haig P. | Chief Development O ... | Sell | S | 50.41 | 12,861 | 648,323 | 129,805 | 142.7 K to 129.8 K (-9.01 %) |